Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it was granted two key patents for lead immuno-oncology candidate asunercept in multiple territories.